Kimball Electronics, Inc. (KE) Q1 2025 Earnings Call Transcript Summary
Kimball Electronics, Inc. (KE) Q1 2025 Earnings Call Transcript Summary
Adjusted operating income was $12.6 million, down from $21 million in Q1 FY 2024.The following is a summary of the Kimball Electronics, Inc. (KE) Q1 2025 Earnings Call Transcript:
以下是kimball electronics，Inc. (KE) 2025財年第一季度業績會議記錄摘要：
Financial Performance:
財務表現:
Kimball Electronics reported a Q1 FY 2025 revenue of $374 million, a 15% decrease year-over-year when excluding AT&M.
Gross margin rate decreased to 6.3%, down 180 basis points from the same quarter last year, primarily due to lower sales absorption.
Adjusted operating income was $12.6 million, down from $21 million in Q1 FY 2024.
Net income was adjusted to $5.5 million, or $0.22 per diluted share.
kimball electronics報告2025財年第一季度營業收入爲37400萬美元，同比減少15%，不含AT&m。
毛利率下降至6.3%，比去年同期下降180個點子，主要是由於銷售吸收較低。
調整後的營業收入爲1260萬美元，較2024財年第一季度的2100萬美元下降。
淨利潤調整爲550萬美元，每股攤薄盈利爲0.22美元。
Business Progress:
業務進展:
Restructured by divesting non-core AT&M business and integrating medical CMO into EMS operations.
Announced the closure of the Tampa manufacturing facility to streamline operations and improve efficiency.
Focused on high-value manufacturing in medical devices and automotive, with new programs launching.
Achieved a $147 million reduction in inventory, enhancing working capital efficiency.
通過剝離非核心AT&m業務並將醫療器械CMO整合到EMS業務中進行重組。
宣佈關閉坦帕製造廠以優化運營並提高效率。
專注於醫療設備和汽車領域的高價值製造，新項目正在啓動。
庫存削減了14700萬美元，提高了營運資本效率。
Opportunities:
機會：
Strategic focus on high-level medical device assemblies and new automotive programs presents growth opportunities.
Continuing restructuring efforts anticipated to bring improved margins and profitability.
戰略聚焦於高水平醫療器械組件和新汽車項目，帶來增長機會。
持續的重組努力預計將帶來改善的毛利率和盈利能力。
Risks:
風險：
Persistent end market softness poses ongoing challenges for demand and revenue.
Closure of the Tampa facility involves risks related to transferring operations and potential disruptions.
持續的終端市場疲軟對需求和營業收入構成持續挑戰。
關閉坦帕設施涉及轉移業務和潛在的風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
